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benzoquinone (CV-6504) against established murine adenocarcinomas
(MAC)
HJ Hussey', MC Bibby2 and MJ Tisdale'
'Pharmaceutical Sciences Institute, Aston University, Birmingham B4 7ET, UK; 2Clinical Oncology Unit, University ofBradford,
Bradford BD7 JDP, UK.
Summary 2,3,5-Trimethyl-6-(3-pyridylmethyl)1,4-benzoquinone (CV-6504), an inhibitor of 5-lipoxygenase and
thromboxane A2 synthase and a scavenger of active oxygen species, has been shown to exhibit profound anti-
tumour activity against three established murine adenocarcinomas (MACs) that are generally refractory to
standard cytotoxic agents. For the cachexia-inducing MAC16 tumour, optimal anti-tumour activity was seen at
dose levels of 10 and 25 mg kg - day-, together with a reversal of cachexia and a doubling of the time to
sacrifice of the animals through cachexia from 8 days to 17 days. The remaining tumour fragments showed
extensive necrosis in regions distal from the blood supply. Growth of the MAC13 tumour was also effectively
suppressed at dose levels between 5 and 50 mg kg-l day- 1, resulting in a specific growth delay between 1.0 and
1.2. Growth of the MAC26 tumour was also inhibited in a concentration-related manner, with doses of 25-
50 mg kg-' day-1 being optimal. Anti-tumour activity towards all three tumours at low dose levels of CV-
6504 was effectively suppressed by concurrent administration of linoleic acid (1 g kg-' day-'), suggesting that
inhibition of linoleate metabolism was responsible for the anti-tumour effect. Tumour sensitivity may be
correlated with increased DT-diaphorase levels that are required to metabolise CV-6504 to the active
hydroquinone, which inhibits 5-lipoxygenase activity.
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There is a growing body of evidence suggesting a role for
polyunsaturated fatty acids (PUFAs), and in particular
linoleic acid (LA) and arachidonic (AA) acid, as tumour
promoters (Welsch, 1987) and as regulators of the growth of
solid tumours (Hussey and Tisdale, 1994) and their metastasis
(Chen et al., 1992). The anti-proliferative but not the anti-
cachectic effect of eicosapentaenoic acid (EPA) against the
MAC16 tumour was reversed by concurrent administration
of LA (Hudson et al., 1993), suggesting that LA released
from adipose tissue during the process of cachexia may be
important for tumour growth. Significantly lower levels of
LA as a percentage of total fatty acids were observed in
plasma phospholipids, and cholesterol esters and in red blood
cell phospholipids in patients with cachexia (Mosconi et al.,
1989) suggesting that human tumours may also be dependent
on this essential fatty acid.
Studies in vitro (Hussey and Tisdale, 1994; Rose and
Connolly, 1990) have suggested that metabolism of PUFA
through the lipoxygenase pathway may be important for
stimulation of tumour growth. Lipoxygenases constitute a
family of closely related non-haeme iron-containing dioxy-
genases that convert PUFA to the corresponding hydro-
peroxy derivatives. In mammalian cells at least four types of
lipoxygenase can be discriminated on the basis of the carbon
atom of the substrate molecule (AA) at which oxygen is
introduced: the 5-lipoxygenase, two 12-lipoxygenases (plate-
let type and leucocyte type) and the 15-lipoxygenases.
Metabolism through the 12-lipoxygenase pathway may be
most important for tumour growth and metastasis. Thus 12-
(S)-hydroxyeicosatetraenoic acid (12(S)-HETE) has been
suggested (Liu et al., 1994) as a determinant of the
metastatic potential of tumour cells and may be a crucial
target for intervention in metastasis. 12(S)-HETE has been
shown to stimulate DNA synthesis in fetal bovine aortic
endothelial cells (Setty et al., 1987) and to regulate
expression of the proto-oncogenes c-fos and c-myc in rat
lens epithelial cells (Lysz et al., 1994), whereas 12(R)-HETE
formed from AA by a cytochrome P450-dependent pathway
caused neovascularisation of the cornea (Masferrer et al.,
1991). This could explain why inhibitors of the AA cascade
exert anti-angiogenic activity in an in vivo model system of
tumour angiogenesis in mice and inhibit tube formation in
vitro (Ito et al., 1993). Growth factors such as epidermal
growth factor (EGF) enhance 12-HETE formation from AA
(Chang et al., 1992) and the hydroxy and hydroperoxy
metabolites of LA enhance EGF-stimulated [3H]thymidine
incorporation in Balb/c 3T3 cells (Glasgow and Eling, 1990),
suggesting that these metabolites may be part of the signal
transduction cascade initiated by EGF.
These results suggest that inhibitors of the lipoxygenase
pathways may provide useful new agents to inhibit tumour
growth and metastasis. A number of inhibitors have been
synthesised, mainly of the 5-lipoxygenase pathway. The
present report concerns the novel anti - tumour activity
of 2,3,5 - trimethyl -6 - (3 -pyridylmethyl) - 1,4 -benzoquinone
(CV-6504) against established colon adenocarcinomas of
the MAC series which are refractory to standard cytotoxic
agents (Double and Bibby, 1989) and which require PUFA
for growth stimulation (Hussey and Tisdale, 1994). CV-6504
has inhibitory activity against both 5 -lipoxygenase and
thromboxane A2 synthase as well as scavenging activity
against active oxygen species (Ohkawa et al., 1991a,b). The
agent has undergone clinical investigation for the treatment
of chronic glomerular nephritis.
Materials and methods
Animals
Pure-strain male NMRI mice were obtained from our own
inbred colony under conventional conditions and were fed a
rat and mouse breeding diet of which 50% of the energy was
supplied by carbohydrate and 11.5% as fat. Linoleic acid
comprised 4.5% of the fat giving a daily consumption of
45 mg (Hussey and Tisdale, 1994). The transplantable mouse
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adenocarcinomas of the colon (MACs) were originally
produced by prolonged administration of 1,2-dimethylhydra-
zine (Double et al., 1975). Three tumours of this series were
used in the present study, MAC16, MAC26 and MAC13
which were transplanted subcutaneously by trocar fragments
into the flank. The MAC16 tumour is associated with
cachexia which appears 9 to 12 days after transplantation
(Bibby et al., 1987). In all cases therapy was initiated 9-12
days after transplantation when the tumour became palpable
and in the case ofthe MAC16 tumour weight loss had started
to occur. Mice were randomised into groups of 8-10. CV-
6504 was supplied by Takeda Chemical Industries, Osaka,
Japan and was administered p.o. daily in aqueous solution
(0.1 ml). Control mice received water alone (0.1 ml). Tumour
dimensions were measured daily by means ofcalipers and the
volume was calculated from the formula:
length x (width)2
2
Animals were killed if the tumour ulcerated, weight loss
reached 25 to 30% of the original body weight, the tumour
weight reached 10% of the host weight or the animals
became moribund as agreed by the Co-ordinating Committee
on Cancer Research of the UK for the welfare of animals
with neoplasms. The experiment was repeated three times
with the MAC16 tumour and twice with the MAC13 and
MAC26 tumours. The results shown in Figures 1, 4, 6 and 7
are representative of a single experiment.
Cell lines
MAC13, MAC26 and MAC16 cell lines were derived from
the solid tumours and maintained in vitro in RPMI-1640
medium supplemented with either 10% (MAC13 and
MAC26) or 5% (MAC16) fetal calf serum at 37°C under
an atmosphere of 5% carbon dioxide in air. For cell growth
assays cells were seeded either at 0.5 (MAC13 and MAC26)
or 2.0 x 104 cells per well (MAC16) and left for 2 h before
drug addition. Cell counts were made 72 h after drug
addition using a ZM Coulter counter.
Histology
Tumour tissue from both control and treated animals was
processed for histological examination. Tumours were fixed
in Bouin's fluid, dehydrated in ethanol and embedded in
paraffin wax. Sections (5 gm) were stained with haematoxylin
and eosin.
Statistical analysis
The data were statistically evaluated using two-way analysis
of variance.
Results
CV-6504 was a potent inhibitor ofthe growth ofthe MAC cell
lines in vitro, the IC50 values (concentration in jUM reducing cell
numbers by 50% 72 h after seeding) being for MAC16, 3 + 1,
for MAC26 7+1 and for MAC13 3 + 1 ,UM. These values were
about 10-fold lower than previously observed with the cyclo-
oxygenase inhibitor indomethacin (Hussey and Tisdale, 1994).
The IC50 value to MAC16 was not increased by extracellular
glutathione levels between 1 and 100 ptM, suggesting that it did
not react with glutathione in vitro.
The MAC tumours are relatively slow growing in vivo
with volume doubling times of 4 days (MAC16), 3.5 days
(MAC13) and 3 days (MAC26) and show varying degrees of
differentiation. The effect of CV-6504 on the growth of the
MAC16 tumour and the effect on host body weight loss is
shown in Figure 1. Therapy was initiated 9 days after
transplantation when the tumour volume was 100 mm3. The
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Figure 1 Effect of oral administration of CV-6504 on tumour
growth (a) and host body weight (b) in male mice transplanted
with the MAC16 tumour. The experiment was initiated 9 days
after tumour transplantation (day 1) and the absolute tumour
volume was 100mm3. Both tumour volume and host body weight
were normalised to 100% on day 1. CV-6504 was administered
p.o. on a daily basis at doses of 5 (0), 10 (A) and 25
(C])mgkg- in water, whereas control animals (x) received
water alone. Differences from control values a, P<0.05 and b,
P<0.01 were determined using two-way ANOVA followed by
Tuckey's test.
volume has been normalised to 100% and the starting point
of the experiment is shown as day 1 in Figure la. Both
tumour growth and host weight loss were inhibited in a
dose-related manner with no significant difference being
observed with doses of 10 and 25 mg kg-' day-'. Both
doses lead to an increased time to sacrifice of the animals
through cachexia without any evidence of toxicity. In fact as
shown in Figure Ib, since cachexia was totally suppressed
the animals actually increased in body weight. The effect on
tumour volume was more pronounced at larger tumour
volumes for the two higher dose levels of CV-6504. Thus for
CV-6504 at 25 mg kg-' the specific growth delay increased
from 0.75 after one doubling to 2.2 after two doublings.
Likewise at 10 mg kg-1 the specific growth delay was only
0.75 after one doubling, but the tumour never reached two
doublings during the 17 days of the experiment. Tumour
growth inhibition, reversal of cachexia and prolongation of
survival produced by CV-6504 at 10 mg kg-' were reduced
when LA (1 g kg-') was administered concomitantly on a
daily basis. Histopathological examination of tumour
fragments remaining after 17 days administration of CV-
6504 (10 mg kg-' day-') (Figure 2) showed evidence of
massive necrosis with few viable tumour cells, fibrosis and
lymphocytic infiltration. Tumour vasculature remained intact
and there was evidence of viable tumour cells around the
blood vessels (Figure 3a). There was extensive necrosis and a
fibrous capsule which walled in the few remaining viable
cells and areas of necrosis (Figure 3b). Control MAC16
tumours showed little necrosis and no capsule (Figure 3c).Effect of a lipoxygenase inhibitor on tumour growth
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Figure 2 Sections through the MAC16 tumour from control
animals at day 6 (a) or after 17 days on CV-6504 at 10mgkg-
day-l (b).
Growth of the MAC13 tumour was also effectively
suppressed by administration of CV-6504 at dose levels
between 5 and 50 mg kg- ' day- ' (Figure 4a). Lower dose
levels (5 and 10 mg kg-' day-') appeared to produce more
effective tumour suppression and a higher specific growth
delay than higher doses (Table I). Growth inhibition
produced by CV-6504 at 5 mg kg-1 day-1 was reduced by
co-administration of LA (1 g kg-1 day-1) (Figure 4b) but
this effect was counteracted by increasing the dose of CV-
6504 to 10 mg kg-1 day-1 (Figure 4c). Histological
examination of sections of treated tumour compared with
control revealed significant morphological effects. Control
sections (Figure 5a) demonstrated the typical glandular
pattern of this tumour, whereas treatment resulted in
central necrosis (Figure 5b, c) with evidence of lymphocyte
infiltration. The effect of lower dose levels of CV-6504 on
growth of the MAC13 tumour was addressed in a second
experiment (Figure 6). This showed that a dose level of
5 mg kg-1 day-' produced a significantly greater growth
inhibition of the MAC13 tumour than did the lower dose
levels.
Growth of the MAC26 tumour was also inhibited by CV-
6504 in a dose-related manner (Figure 7). This tumour was
less sensitive to CV-6504 than the other MAC tumours and
dose levels of 25 and 50 mg kg-' day-' were found to be
optimal (Table I). Again a reduction of the anti-tumour
effect of CV-6504 (25 mg kg-' day-') was observed with
concurrent administration of LA (1 g kg-1 day-').
Discussion
Previous studies (Double and Bibby, 1989) have demon-
strated the MAC tumour series to be generally refractory to
standard cytotoxic agents, with the MAC13 probably being
50Qum
Figure 3 (a) Section through the MAC16 tumour after 17 days
treatment with CV-6504 at 10mgkg-1 day-' showing viable
tumour cells around the blood vessels and the presence of a
fibrous capsule (b). Section through a control MAC16 tumour (c)
showing the absence of the fibrous capsule.
the most responsive. In contrast with this general lack of
responsiveness the present study demonstrates profound anti-
tumour activity of CV-6504 against three established MAC
tumours in an in vivo assay. For most anti-tumour agents
activity is usually only demonstrated at the maximum
tolerated dose. Thus the therapeutic index for the standard
nitrosoureas against chemoresponsive tumours such as the
MAC13 is <1 and even against the L1210 leukaemia is no
higher than 7 (Double and Bibby, 1989). This study
demonstrates optimal anti-tumour activity of CV-6504
against the MAC16 tumour at 10 mg kg-' day-', against
the MAC13 tumours at 5 - 10 mg kg ' day ' and against the
MAC26 tumour at 50 mg kg- day-'. Chronic toxicity
studies showed that the non-toxic dosage level in male mice
was 100 mg kg-' day-'. Thus CV-6504 not only demon-
strated profound anti-tumour activity against previously
chemoresistant animal models, but did so at a dose with a
high margin of safety. This dose is comparable with that
previously employed for the inhibition of puromycinEffect of a lipoxygenase inhibitor on tumour growth
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Figure 4 Effect of oral administration of CV-6504 on tumour
growth of mice transplanted with the MAC13 tumour in the
absence (a) or presence (b and c) of LA ( gkg'- day-). The
experiment was initiated 9 days after tumour transplantation and
the initial tumour volume was 91 + 10mm3, which has been
normalised to 100% on day 1. Animals were treated daily with
CV-6504 at 5 (0), 10 (A), 25 (0l) or 50 (A)mgkg- in water
while control animals (x) received water alone; or (b and c) LA
(0) plus (b) CV-6504 at 5 and (c) 10mgkg' (U). Differences (a,
P=0.05 and b P=0.01) from control tumour volume given water
alone and (C, P= 0.05 and d, P= 0.01) given LA were determined
by two-way ANOVA followed by Tuckey's test.
Table I Specific growth delay induced by CV-6504a
Tumour type
CV-6504 (mg/kg- ') MACJ6 MACJ3 MAC26
5 0.7 1.2 ND
10 _b 1.2 ND
25 2.2 1.0 0.8
50 ND 1.0 1.2
aDetermined after two tumour doublings.bAt this dose level the
tumour did not reach two doublings. ND, not determined.
aminonucleoside nephrosis in rats (Shibouta et al., 1991).
The MAC16 tumour was found to be more responsive to
CV-6504 than the MAC26 tumour (Table I). Mitomycin C
and doxorubicin are the only two other chemotherapeutic
agents which are more effective against MAC16 than
Figure 5 Histological appearance of control MAC13 tumour (a)
and changes seen following treatment with oral CV-6504 at
25mgkg- day-'. (b) illustrates a large area of necrosis which
was typical of treated tumours. The appearance of the necrotic
changes is shown in more detail in (c).
MAC26 (Double and Bibby, 1989). These are also
quinone-containing drugs that can undergo metabolic
reduction and for mitomycin C there is evidence to suggest
activation by DT-diaphorase (Siegal et al., 1990). Previous
studies on the mode of action of CV-6504 suggest a
reduction to the hydroquinone by two electron-donating
enzymes such as DT-diaphorase without the intermediary of
a semiquinone radical (Ohkawa et al., 1991b). Lipid
peroxidation as well as 5-lipoxygenase activity is prevented
by reducing the ferric iron in the active site of the enzyme to
the ferrous (resting state) and unlike a number of anti-
tumour quinones, CV-6504 is capable of scavenging active
oxygen species. The increased sensitivity of the MAC16 to
CV-6504 could be correlated with an increased DT-
diaphorase activity that has been reported to be 16-fold
higher than in the MAC26 tumour (Collard, 1994) with the
MAC13 tumour displaying a similar low value. Certainly
CV-6504 is an excellent substrate for both human and
mouse DT-diaphorase with a kcat of 6 x 104 min-' and Km of
50 gIM (RJ Knox, Personal communication). These results
can be compared with the classic DT-diaphorase substrate
menadione, which has the same kcat, but a Km of only
1000
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Figure 6 Effect of daily administration of CV-6504 at 1(E), 2.5
(C) and 5 (0)mgkg 1 on the increase in tumour volume ofmice
bearing the MAC13 tumour. Differences from control values
(a P<0.05 and b, P<0.01) and from the Imgkg1 group
(C, P<0.05 andd, P<0.01) were determined by two-way ANOVA
followed by Tuckey's test.
3.1 gM. However, recent results raise doubts that the
increased drug sensitivity of tumours with high levels of
DT-diaphorase is caused by their increased DT-diaphorase
activity (Powis et al., 1995). There are other enzymes which
can also activate anti-tumour quinones, but it is not known
how these vary between different tumour types.
Histological studies suggest that drug toxicity towards the
MAC16 tumour is manifested in regions distant from the
vascular supply. Such regions might be considered to be
hypoxic and would generally be relatively inaccessible to
drugs and would contain predominantly non-cycling cells.
However, such cells may display increased levels of DT-
diaphorase activity, since recent studies (Phillips et al., 1994)
using multicellular spheroids indicate gene expression for
this enzyme is elevated in cells close to the necrotic centre.
Cytotoxicity of quinones decreases with increasing methyl
substitution of the nucleus with the higher redox potential
benzoquinones being the most cytotoxic (O'Brien, 1991).
The fully substituted benzoquinone 2,3,5,6 tetramethyl-
benzoquinone (duroquinone) does not form glutathione
conjugates or alkylate proteins and is only weakly
cytotoxic. It may be expected by comparison that CV-6504
would also show low reactivity, which would explain the
lack of effect of glutathione on cytotoxicity in vitro and the
low toxicity to the whole animal.
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Figure 7 Effect ofdaily oral administration of CV-6504 at 25(E)
or 50(A)mgkg- or with 25mgkg-I and 1 gkg- 1 LA (-) on the
growth of the MAC26 tumour as compared with control groups
treated with solvent alone (x) or with LA (1 gkg-1) (0). The
experiment was initiated 10 days after tumour transplantation and
the initial tumour volume was 82mm3, which has been normalised
to 100% on day 1.
Anti-tumour activity of CV-6504 towards the MAC16,
MAC13 and MAC26 tumours at low dose levels was
reduced by the concomitant administration of pure LA
(1 g kg-' day-'). This suggests that the anti-tumour effect of
CV-6504 is mediated through inhibition of the metabolism
of LA. Higher dose levels of the drug were able to overcome
the effect of LA suggesting a competitive effect. Further
studies are required to completely evaluate the mode of
action of this novel agent and in particular which pathway
of LA metabolism is related to the anti-tumour activity.
However, the wide spectrum of anti-tumour activity, against
what are generally considered to be chemoresistant tumours,
combined with a high measure of safety, identifies CV-6504
as a potential agent for clinical investigation.
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